Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates

References

• Highlights from the Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization. 4–7 April 2022
   Google Scholar
• Mouro V, Fischer A. Dealing with a mucosal viral pandemic: lessons from COVID-19 vaccines. Mucosal Immunol. 2022 Apr;15(4):584–594. doi:10.1038/s41385-022-00517-8.
   PubMed Web of Science ®Google Scholar
• Dhama K, Dhawan M, Tiwari R, et al. COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges. Hum Vaccin Immunother. 2022 Nov 30;18(5):2045853.
   PubMed Web of Science ®Google Scholar
• Organisation WH. Strategy to achieve global Covid-19 vaccination by mid-2022. 2021 Oct 6.
   Google Scholar
• Available from: https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html.
   Google Scholar
• Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021 Feb 20;397(10275):671–681.
   PubMed Web of Science ®Google Scholar
• Logunov DY, Dolzhikova IV, Zubkova OV, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020 Sep 26;396(10255):887–897.
   Google Scholar
• Pang NY, Pang AS, Chow VT, et al. Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice. Mil Med Res. 2021 Aug 31;8(1):47.
   PubMed Web of Science ®Google Scholar
• Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021 Jul;27(7):1205–1211.
   PubMed Web of Science ®Google Scholar
• Ejemel M, Li Q, Hou S, et al. A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction. Nat Commun. 2020 Aug 21;11(1):4198.
   PubMed Web of Science ®Google Scholar
• Renegar KB, Small P Jr, Boykins LG, et al. Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J Immunol. 2004 Aug 1;173(3):1978–1986.
   PubMed Web of Science ®Google Scholar
• Zhao J, Zhao J, Perlman S. T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice. J Virol. 2010 Sep;84(18):9318–9325.
   PubMed Web of Science ®Google Scholar
• Truckenmiller ME, Norbury CC. Viral vectors for inducing CD8+ T cell responses. Expert Opin Biol Ther. 2004 Jun;4(6):861–868.
   PubMed Web of Science ®Google Scholar
• McMahan K, Yu J, Mercado NB, et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature. 2021 Feb;590(7847):630–634.
   PubMed Web of Science ®Google Scholar
• Bange EM, Han NA, Wileyto P, et al. CD8(+) t cells contribute to survival in patients with COVID-19 and hematologic cancer. Nat Med. 2021 Jul;27(7):1280–1289.
   PubMed Web of Science ®Google Scholar
• Khalil BA, Elemam NM, Maghazachi AA. Chemokines and chemokine receptors during COVID-19 infection. Comput Struct Biotechnol J. 2021;19:976–988.
   PubMed Web of Science ®Google Scholar
• Anderson KG, Sung H, Skon CN, et al. Cutting edge: intravascular staining redefines lung CD8 T cell responses. J Immunol. 2012 Sep 15;189(6):2702–2706.
   PubMed Web of Science ®Google Scholar
• Harkema JR. Comparative pathology of the nasal mucosa in laboratory animals exposed to inhaled irritants. Environ Health Perspect. 1990 Apr;85:231–238.
   PubMed Web of Science ®Google Scholar
• Harkema JR, Carey SA, Wagner JG. The nose revisited: a brief review of the comparative structure, function, and toxicologic pathology of the nasal epithelium. Toxicol Pathol. 2006;34(3):252–269.
   PubMed Web of Science ®Google Scholar
• Logunov DY, Dolzhikova IV, Zubkova OV, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020 Sep 26;396(10255):887–897.
   PubMed Web of Science ®Google Scholar
• Tukhvatulin AI, Dolzhikova IV, Shcheblyakov DV, et al. An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine “Sputnik Light” for prevention of coronavirus infection in healthy adults. Lancet Reg Health Eur. 2021 Dec;11:100241.
   PubMedGoogle Scholar
• Mietsch M, Paque K, Drummer C, et al. The aging common marmoset's immune system: from junior to senior. Am J Primatol. 2020 Jun;82(6):e23128.
   PubMed Web of Science ®Google Scholar
• Bao L, Deng W, Huang B, et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature. 2020 Jul;583(7818):830–833.
   PubMed Web of Science ®Google Scholar
• Winkler ES, Bailey AL, Kafai NM, et al. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat Immunol. 2020 Nov;21(11):1327–1335.
   PubMed Web of Science ®Google Scholar
• Guo C, Peng Y, Lin L, et al. A pathogen-like antigen-based vaccine confers immune protection against SARS-CoV-2 in non-human primates. Cell Rep Med. 2021 Nov 16;2(11):100448.
   PubMedGoogle Scholar
• WHO. Draft landscape of COVID-19 candidate vaccines. 27 May, 2022. 2022 May 27, [cited 2022 May 27]. Available from: https://wwwwhoint/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
   Google Scholar
• Lavelle EC, Ward RW. Mucosal vaccines - fortifying the frontiers. Nat Rev Immunol. 2022 Apr;22(4):236–250.
   PubMed Web of Science ®Google Scholar
• Karczmarzyk K, Kesik-Brodacka M. Attacking the intruder at the gate: prospects of mucosal anti SARS-CoV-2 vaccines. Pathogens. 2022 Jan 19;11(2):117.
   PubMed Web of Science ®Google Scholar
• Focosi D, Maggi F, Casadevall A. Mucosal vaccines, sterilizing immunity, and the future of SARS-CoV-2 virulence. Viruses. 2022 Jan 19;14(2):187.
   PubMed Web of Science ®Google Scholar
• Furuyama W, Shifflett K, Pinski AN, et al. Rapid protection from COVID-19 in nonhuman primates vaccinated intramuscularly but Not intranasally with a single dose of a vesicular stomatitis virus-based vaccine. Mbio. 2022 Jan 11: e0337921.
   PubMed Web of Science ®Google Scholar
• Dolscheid-Pommerich R, Bartok E, Renn M, et al. Correlation between a quantitative anti-SARS-CoV-2 IgG ELISA and neutralization activity. J Med Virol. 2022 Jan;94(1):388–392.
   PubMed Web of Science ®Google Scholar
• Fausther-Bovendo H, Kobinger GP. Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what's important? Hum Vaccin Immunother. 2014;10(10):2875–2884.
   PubMed Web of Science ®Google Scholar
• Available from: https://graphics.reuters.com/world-coronavirus-tracker-and-maps/vaccination-rollout-and-access/.
   Google Scholar
• Quah BJ, Warren HS, Parish CR. Monitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester. Nat Protoc. 2007;2(9):2049–2056.
   PubMed Web of Science ®Google Scholar
• Roederer M. Interpretation of cellular proliferation data: avoid the panglossian. Cytometry A. 2011 Feb;79(2):95–101.
   PubMedGoogle Scholar
• Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints. Am J Epidemiol. 1938;27(3):493–497.
   Google Scholar